ArticleBioengineering (Basel, Switzerland)2022
Contribution of Deep Learning in the Investigation of Possible Dual LOX-3 Inhibitors/DPPH Scavengers: The Case of Recently Synthesized Compounds.
Article in Bioengineering (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Even though non-steroidal anti-inflammatory drugs are the most effective treatment for inflammatory conditions, they have been linked to negative side effects. A promising approach to mitigating potential risks, is the development of new compounds able to combine anti-inflammatory with antioxidant activity to enhance activity and reduce toxicity. The implication of reactive oxygen species in inflammatory conditions has been extensively studied, based on the pro-inflammatory properties of generated free radicals. Drugs with dual activity (i.e., inhibiting inflammation related enzymes, e.g., LOX-3 and scavenging free radicals, e.g., DPPH) could find various therapeutic applications, such as in cardiovascular or neurodegenerating disorders. The challenge we embarked on using deep learning was the creation of appropriate classification and regression models to discriminate pharmacological activity and selectivity as well as to discover future compounds with dual activity prior to synthesis. An accurate filter algorithm was established, based on knowledge from compounds already evaluated in vitro, that can separate compounds with low, moderate or high activity. In this study, we constructed a customized highly effective one dimensional convolutional neural network (CONV1D), with accuracy scores up to 95.2%, that was able to identify dual active compounds, being LOX-3 inhibitors and DPPH scavengers, as an indication of simultaneous anti-inflammatory and antioxidant activity. Additionally, we created a highly accurate regression model that predicted the exact value of effectiveness of a set of recently synthesized compounds with anti-inflammatory activity, scoring a root mean square error value of 0.8. Eventually, we succeeded in observing the manner in which those newly synthesized compounds differentiate from each other, regarding a specific pharmacological target, using deep learning algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.